Catalyst Wire Dossier Catalyst Wire Dossier

VX-222

VX-222 · Vertex Pharmaceuticals Incorporated
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for VX-222, covering 2014-07-04 to 2014-10-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis [Phase 2]

See pricing